Inhibition of Protein Synthesis Induced by CHK1 Inhibitors Discriminates Sensitive from Resistant Cancer Cells.

Area of Science:

• Molecular Biology
• Cancer Biology
• Pharmacology

Background:

• Checkpoint kinase 1 (CHK1) is crucial for preventing cell division with unrepaired DNA damage.
• CHK1 inhibitors (CHK1i) enhance DNA-damaging drug efficacy and can exhibit single-agent cytotoxicity.
• Understanding CHK1i single-agent activity mechanisms is key for patient stratification and targeted therapies.

Purpose of the Study:

• To investigate the mechanisms of single-agent cytotoxicity induced by the CHK1 inhibitor LY2606368.
• To compare the cellular responses of sensitive and resistant cell lines to LY2606368.
• To elucidate the signaling pathways involved in LY2606368-induced cell death.

Main Methods:

• Treatment of various cell lines with the selective CHK1 inhibitor LY2606368.
• Analysis of protein synthesis, DNA damage, DNA repair, and cell viability.
• Investigation of signaling pathways including cyclin A/CDK2, MUS81, and AMPK.

Main Results:

• Sensitive cells exhibited cell death, inhibited protein synthesis, increased DNA damage, and impaired DNA repair upon LY2606368 treatment.
• Resistant cells showed growth inhibition or cytostasis but not cell death.
• LY2606368-induced DNA damage activated cyclin A/CDK2, MUS81, and AMPK, leading to protein synthesis inhibition; MUS81 and AMPK inhibition modulated cell fate.

Conclusions:

• Single-agent activity of CHK1i like LY2606368 is linked to protein synthesis inhibition in sensitive cells.
• The pathway involves CHK1 inhibition, DNA damage, MUS81 activation, AMPK activation, and subsequent protein synthesis suppression.
• Distinguishing cell death from cytostasis is critical for evaluating therapeutic potential of CHK1i in cancer treatment.